Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04298463 |
Other study ID # |
146(A)PO18530 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
June 18, 2020 |
Est. completion date |
May 19, 2021 |
Study information
Verified date |
February 2022 |
Source |
Aziende Chimiche Riunite Angelini Francesco S.p.A |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The aim of this study is to collect the data on the effectiveness of dalbavancin in terms of
save of hospitalization days on patients treated between June 2017 and June 2019 in two
countries (Italy and Greece) vs the other Standards of care of the same class (SoC; i.v. lipo
and glycopeptides) in a real-life context.
Time to discharge from the start of therapy for ABSSSI in the hospital context will be
assessed and all relevant data available on patient management, clinical, microbiological and
safety outcomes during hospitalization and in the follow-up visits up to 30 days from
discharge will be collected and evaluated.
Description:
Acute bacterial skin and skin structure infections (ABSSSI), formally referred to as
complicated skin and soft tissue infections, include infections such as
cellulitis/erysipelas, wound infection, and major cutaneous abscess and have a minimum lesion
surface area of approximately 75 cm2. The regulatory definitions of major abscess,
cellulitis, and wound infection may not align with practice-based criteria. Common bacterial
pathogens causing ABSSSI are Streptococcus pyogenes and Staphylococcus aureus including
Methicillin-Resistant Staphylococcus Aureus (MRSA). Less common causes include other
Streptococcus species, Enterococcus faecalis, or Gram-negative bacteria.
Increasing dramatically in incidence, a challenging medical problem associated with high
direct and indirect costs has been highlighted for both the medical system and society.
Over the last decade, there was a witnessed a dramatic increase in the incidence of community
acquired skin infections, an increasing proportion of which are a consequence of MRSA,
reinforcing the need for new and effective antibacterial therapies in this disease.
In this context, research has been promoted to develop new antibiotics capable to fight MRSA,
the most common multi-drug-resistant Gram+ bacterium in Europe, and to overcome the
limitations of the most widely used antibiotics, such as vancomycin, teicoplanin, and β-
lactams. These new antibiotics (lipoglycopeptides and new oxazolidinones) have innovative
characteristics that make them interesting for the specific treatment of ABSSSIs. Dalbavancin
is one of these new antibiotics. Dalbavancin is a lipoglycopeptide with activity against
Grampositive organisms, including MRSA, through interference with bacterial cell wall
formation by preventing cross-linking of peptidoglycans. Dalbavancin has a distinctive
pharmacokinetic profile, with a terminal half-life of 14.4 days, which allows for infrequent
or even single intravenous dosing.
This new long-acting antibiotic represents a potential opportunity for early discharge. This
approach could profoundly modify the management of these infections by reducing or in some
cases eliminating hospitalization costs and risks.